• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 6:23:10 AM ET
    $CERC
    Major Pharmaceuticals
    Health Care
    Get the next $CERC alert in real time by email
    SC 13G 1 tm216457d27_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    CERECOR INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    15671L109

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x  Rule 13d-1(b)
      ¨  Rule 13d-1(c)
      ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO.  15671L109 Page 2 of 7 Pages

     

    CUSIP No.  15671L109
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 6,233,316
    (7) Sole dispositive power 0
    (8) Shared dispositive power 6,233,316
    (9) Aggregate amount beneficially owned by each reporting person 6,233,316
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.3%
    (12) Type of reporting person (see instructions) IA

     

     

     

    CUSIP NO.  15671L109 Page 3 of 7 Pages

     

    CUSIP No.  15671L109
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 6,233,316
    (7) Sole dispositive power 0
    (8) Shared dispositive power 6,233,316
    (9) Aggregate amount beneficially owned by each reporting person 6,233,316
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.3%
    (12) Type of reporting person (see instructions) HC

     

     

     

    CUSIP NO.  15671L109 Page 4 of 7 Pages

     

    CUSIP No.  15671L109
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 6,233,316
    (7) Sole dispositive power 0
    (8) Shared dispositive power 6,233,316
    (9) Aggregate amount beneficially owned by each reporting person 6,233,316
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.3%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      CERECOR INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      540 Gaither Road, Suite 400, Rockville, Maryland 20850
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

      Common Stock, $0.001 par value (the “Shares”).

     

     

     

    CUSIP NO.  15671L109 Page 5 of 7 Pages

     

    Item 2(e). CUSIP Number:
     

     

    15671L109

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

    Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2020, Nantahala may be deemed to be the beneficial owner of 6,233,316 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. 

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2020, each of the Reporting Persons may be deemed to be the beneficial owner of 8.3% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 9, 2020, there were 74,910,047 Shares outstanding as of November 5, 2020).

     

     

     

    CUSIP NO.  15671L109 Page 6 of 7 Pages

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 6,233,316
      (iii) Sole power to dispose or to direct the disposition of 0

    (iv) Shared power to dispose or to direct the disposition of 6,233,316
       
     

    Each of Messrs. Harkey and Mack:

       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 6,233,316
      (iii) Sole power to dispose or to direct the disposition of 0

    (iv) Shared power to dispose or to direct the disposition of 6,233,316

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.

     

     

     

    CUSIP NO.  15671L109 Page 7 of 7 Pages

     

    Item 10. Certification:
       
      By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 16, 2021 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Paul E. Rehm
        Paul E. Rehm
        Chief Compliance Officer
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $CERC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      10/14/21 9:01:02 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cerecor Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/21/21 4:51:43 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/17/21 3:04:41 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Financials

    Live finance-specific insights

    See more
    • Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

      Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p

      7/26/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Maher Illya Keith

      3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/22/21 7:45:39 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Bruhn Suzanne Louise

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:48:25 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Gutry Phil

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:45:42 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CERC
    Leadership Updates

    Live Leadership Updates

    See more

    $CERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

      Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa

      8/26/21 7:30:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

      Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre

      8/2/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

      ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma

      8/2/21 7:30:00 AM ET
      $CERC
      $HRZN
      Major Pharmaceuticals
      Health Care
      Finance: Consumer Services
      Finance
    • Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs

      MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun

      3/15/21 8:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Appoints Schond L. Greenway as Chief Financial Officer

      ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Mr. Greenway comes to Cerecor with over 20 years’ experience in investment banking, finance and corporate advisory and investment analysis in the life sciences and financial services industries. Chris Sullivan, who has served as the Company’s Interim Chief Financial Officer for the past year, will continue with the Company as its Chief Accounting

      3/1/21 7:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cantor Fitzgerald initiated coverage on Cerecor with a new price target

      Cantor Fitzgerald initiated coverage of Cerecor with a rating of Overweight and set a new price target of $7.00

      6/4/21 7:42:32 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor upgraded by Maxim Group with a new price target

      Maxim Group upgraded Cerecor from Hold to Buy and set a new price target of $7.00

      4/21/21 9:51:06 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Jefferies initiated coverage on Cerecor with a new price target

      Jefferies initiated coverage of Cerecor with a rating of Buy and set a new price target of $4.00

      4/20/21 7:17:47 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    SEC Filings

    See more
    • Cerecor Inc. filed SEC Form 8-K: Leadership Update

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      10/18/21 4:11:35 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:44:34 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 424B5 filed by Cerecor Inc.

      424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:41:54 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care